HC Wainwright & Co. Upgrades Iterum Therapeutics to Buy, Maintains Price Target to $6
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce upgraded Iterum Therapeutics (NASDAQ:ITRM) from Neutral to Buy while maintaining the price target at $6. This upgrade reflects a positive outlook on the company's future performance.

February 07, 2024 | 11:30 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Iterum Therapeutics was upgraded by HC Wainwright & Co. from Neutral to Buy, with the price target maintained at $6, indicating a positive outlook on the company's future performance.
Upgrades by analysts, especially from neutral to buy, often lead to positive short-term price movements as they reflect a positive change in the analyst's view on the company's future performance. Maintaining a price target of $6 suggests that the analyst sees the company reaching or maintaining this value in the near future, further indicating a positive outlook.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100